As of November 6, 2026, 2 holders' latest Schedule 13D or 13G filings report owning 5% or more of Protalix BioTherapeutics, Inc. The largest reported stake is HOLD Alapkezelo Zrt.'s, at 5.2%. 4 filings are on record since March 4, 2026 (Schedule 13G, October 15, 2026).
Sell to companies like Protalix BioTherapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: HOLD Alapkezelo Zrt. · Sole voting: 4,157,791 · Shared voting: 0 · Sole dispositive: 4,157,791 · Shared dispositive: 0 · SCHEDULE 13G, 2026-10-15
- · Reporting person: BlackRock, Inc. · Sole voting: 3,982,603 · Shared voting: 0 · Sole dispositive: 4,046,650 · Shared dispositive: 0 · SCHEDULE 13G, 2026-07-29
- · Reporting person: MAK Capital Fund LP · Sole voting: 0 · Shared voting: 3,616,289 · Sole dispositive: 0 · Shared dispositive: 3,616,289 · SCHEDULE 13G/A, 2026-03-30
- · Holder: MAK Capital Fund LP · Percent: 5.8% · SCHEDULE 13G
Protalix BioTherapeutics, Inc. has 4 Schedule 13D or 13G filings on record since 2026-03-04. 2 holders' latest filing reports 5% or more of common shares. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| 5.2% | 4,157,791 | SCHEDULE 13G, 2026-10-15 | 2026-10-14 | |
| BlackRock, Inc. | 5.02% | 4,046,650 | SCHEDULE 13G, 2026-07-29 | 2026-06-30 |
| MAK Capital Fund LP | 4.5% | 3,616,289 | SCHEDULE 13G/A, 2026-03-30 | 2026-03-24 |
Holding shares or following this stake? See who's behind Protalix BioTherapeutics, Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on Protalix BioTherapeutics, Inc. and the records around it.
Protalix BioTherapeutics, Inc. elsewhere on the record
Companies that share a holder
- HOLD Alapkezelo Zrt. also filed stake reports on 2 other companies: PERMA FIX ENVIRONMENTAL SERVICES INC (Oct 2026), MediWound Ltd. (Aug 2026)
- MAK Capital Fund LP also filed stake reports on 7 other companies: Comstock Inc. (Oct 2026), Autolus Therapeutics plc (May 2026), ClearPoint Neuro, Inc. (May 2026)
- BlackRock, Inc. also filed stake reports on 1596 other companies: AvePoint, Inc. (Nov 2026), BIOMARIN PHARMACEUTICAL INC (Nov 2026), MSG RANGERS CORP (Nov 2026)
Watch Protalix BioTherapeutics, Inc.
Get an email when Protalix BioTherapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Protalix BioTherapeutics, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Protalix BioTherapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Protalix BioTherapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
4 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| HOLD Alapkezelo Zrt. | 4,157,791 | 0 | 4,157,791 | 0 | SCHEDULE 13G, 2026-10-15 |
| BlackRock, Inc. | 3,982,603 | 0 | 4,046,650 | 0 | SCHEDULE 13G, 2026-07-29 |
| MAK Capital Fund LP | 0 | 3,616,289 | 0 | 3,616,289 | SCHEDULE 13G/A, 2026-03-30 |
| Mak Capital One LLC | 0 | 3,616,289 | 0 | 3,616,289 | SCHEDULE 13G/A, 2026-03-30 |
| Kaufman Michael A | 0 | 3,616,289 | 0 | 3,616,289 | SCHEDULE 13G/A, 2026-03-30 |
The latest filing identifies Protalix BioTherapeutics, Inc. by CUSIP 74365A309 and gives its principal executive office as 2 UNIVERSITY PLAZA, SUITE 100, HACKENSACK, NJ 07601 (SCHEDULE 13G, 2026-10-15).
What the percentages are based on
4.5% The calculation is based upon 3,616,289 shares of Common Stock beneficially owned as of 03/30/2026 and a total of 80,421,181 shares of Common Stock, $0.001 par value per share, outstanding as of November 1, 2025, as reported by the Issuer in its Form 10-Q filed November 13, 2025.MAK Capital Fund LP, SCHEDULE 13G/A, 2026-03-30
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2026-03-04 | MAK Capital Fund LP | 5.8% | SCHEDULE 13G |
| 2026-03-30 | MAK Capital Fund LP | 4.5% | SCHEDULE 13G/A |
| 2026-07-29 | BlackRock, Inc. | 5.02% | SCHEDULE 13G |
| 2026-10-15 | HOLD Alapkezelo Zrt. | 5.2% | SCHEDULE 13G |
Questions about who owns Protalix BioTherapeutics, Inc.
Who owns Protalix BioTherapeutics, Inc.?
On this page, 2 holders' latest ownership filings report 5% or more of Protalix BioTherapeutics, Inc.: HOLD Alapkezelo Zrt. (5.2%, Schedule 13G, filed 2026-10-15) and BlackRock, Inc. (5.02%, Schedule 13G, filed 2026-07-29).
Who are the largest shareholders of Protalix BioTherapeutics, Inc.?
By the share each holder's latest filing reports, the largest holders of Protalix BioTherapeutics, Inc. on this page are HOLD Alapkezelo Zrt. (5.2%) and BlackRock, Inc. (5.02%).
When did HOLD Alapkezelo Zrt. buy into Protalix BioTherapeutics, Inc.?
The filings give report dates, not purchase dates. The earliest filing from HOLD Alapkezelo Zrt. on this page is the Schedule 13G, filed 2026-10-15, reporting 5.2%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 4 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Tools for this story
Each opens in a new tab, filled in for Protalix BioTherapeutics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.